{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T04:06:20Z","timestamp":1794283580366,"version":"4.9.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T00:00:00Z","timestamp":1745280000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002839","name":"Charit\u00e9 - Universit\u00e4tsmedizin Berlin","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002839","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Leptomeningeal disease (LMD) is a fatal complication of cancer linked to poor survival rates and limited treatment options. While photon involved-field radiotherapy is the standard of care for local palliation and symptom alleviation, it lacks durable disease control. Recent data suggest proton craniospinal irradiation (pCSI) to be a promising treatment option, potentially prolonging progression-free survival (PFS) and overall survival (OS). Herein, we report our initial experience with pCSI for treating LMD from solid malignancies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adult patients treated with pCSI for LMD were identified, with analysis of patient, tumor, and treatment characteristics as well as clinical outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Nine patients were eligible for analysis who were treated between February 2023 and February 2024. The median age at pCSI and Karnofsky performance status (KPS) were 58.6 years and 80%, respectively. The primary disease was breast cancer in 33.3%, and LMD involved both the brain and spine in 55.5%. Approximately half of the patients (55.5%) had a cerebrospinal fluid diversion before treatment, and nearly all patients underwent pCSI with 30\u00a0Gy (relative biological effectiveness) in 10 fractions. All patients completed pCSI as planned. The median clinical and central nervous system (CNS) radiographic follow-up periods were both 3.5 months. Six deaths were observed during the available follow-up. The median PFS, CNS PFS, and OS were 2.7, 4.0, and 4.0 months, respectively. Younger age, higher KPS, and concurrent treatment with targeted therapy were associated with longer OS, while cases with LMD involving both the brain and spine had shorter survival. The observed toxicity was manageable, without any occurrence of grade 4 or 5 toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>pCSI can be an effective and safe treatment option for a highly selected population of patients with LMD. Further data and prospective studies are warranted to clarify its role in the management of LMD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13014-025-02618-7","type":"journal-article","created":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T10:48:05Z","timestamp":1745318885000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Early experience with proton craniospinal irradiation in adult patients with leptomeningeal disease"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6177-1755","authenticated-orcid":false,"given":"Felix","family":"Ehret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ammy M.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariel E.","family":"Marciscano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Zieminski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peggy A.","family":"Leland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melin J.","family":"Khandekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin S.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen A.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,22]]},"reference":[{"issue":"1","key":"2618_CR1","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/cncr.30911","volume":"124","author":"N Wang","year":"2018","unstructured":"Wang N, Bertalan MS, Brastianos PK. Leptomeningeal metastasis from systemic cancer: review and update on management. Cancer. 2018;124(1):21\u201335.","journal-title":"Cancer"},{"key":"2618_CR2","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.3389\/fonc.2019.01224","volume":"9","author":"SM Buszek","year":"2019","unstructured":"Buszek SM, Chung C. Radiotherapy in leptomeningeal disease: a systematic review of randomized and non-randomized trials. Front Oncol. 2019;9:1224.","journal-title":"Front Oncol"},{"key":"2618_CR3","doi-asserted-by":"crossref","unstructured":"Wilcox JA et al. Leptomeningeal metastases from solid tumors: a SNO and ASCO consensus review on clinical management and future directions. Neuro Oncol. 2024 Oct 3;26(10):1781\u2013804.","DOI":"10.1093\/neuonc\/noae103"},{"issue":"18","key":"2618_CR4","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1212\/WNL.0b013e3181dc1a69","volume":"74","author":"JL Clarke","year":"2010","unstructured":"Clarke JL, et al. Leptomeningeal metastases in the MRI era. Neurology. 2010;74(18):1449\u201354.","journal-title":"Neurology"},{"key":"2618_CR5","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3389\/fonc.2018.00641","volume":"8","author":"RA El Shafie","year":"2018","unstructured":"El Shafie RA, et al. Palliative radiotherapy for leptomeningeal carcinomatosis-analysis of outcome, prognostic factors, and symptom response. Front Oncol. 2018;8:641.","journal-title":"Front Oncol"},{"issue":"1","key":"2618_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1186\/s12885-020-06984-1","volume":"20","author":"M Devecka","year":"2020","unstructured":"Devecka M, et al. Craniospinal irradiation(CSI) in patients with leptomeningeal metastases: risk-benefit-profile and development of a prognostic score for decision making in the palliative setting. BMC Cancer. 2020;20(1):501.","journal-title":"BMC Cancer"},{"issue":"1","key":"2618_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1093\/neuonc\/noaa152","volume":"23","author":"TJ Yang","year":"2021","unstructured":"Yang TJ, et al. Clinical trial of proton craniospinal irradiation for leptomeningeal metastases. Neuro Oncol. 2021;23(1):134\u201343.","journal-title":"Neuro Oncol"},{"issue":"33","key":"2618_CR8","doi-asserted-by":"publisher","first-page":"3858","DOI":"10.1200\/JCO.22.01148","volume":"40","author":"JT Yang","year":"2022","unstructured":"Yang JT, et al. Randomized phase II trial of proton craniospinal irradiation versus photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis. J Clin Oncol. 2022;40(33):3858\u201367.","journal-title":"J Clin Oncol"},{"key":"2618_CR9","doi-asserted-by":"crossref","unstructured":"Lam K et al. Early outcomes from proton craniospinal irradiation for leptomeningeal metastasis from solid tumors. Adv Radiat Oncol. 2024 Dec 2;10(2):101697.","DOI":"10.1016\/j.adro.2024.101697"},{"issue":"3","key":"2618_CR10","doi-asserted-by":"publisher","first-page":"Cns101","DOI":"10.2217\/cns-2023-0005","volume":"12","author":"MJ Webb","year":"2023","unstructured":"Webb MJ, et al. Proton craniospinal irradiation with bevacizumab and pembrolizumab for leptomeningeal disease: a case report. CNS Oncol. 2023;12(3):Cns101.","journal-title":"CNS Oncol"},{"issue":"1","key":"2618_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.36401\/JIPO-23-20","volume":"7","author":"U Sener","year":"2024","unstructured":"Sener U, et al. Proton craniospinal irradiation with immunotherapy in two patients with leptomeningeal disease from melanoma. J Immunother Precis Oncol. 2024;7(1):1\u20136.","journal-title":"J Immunother Precis Oncol"},{"key":"2618_CR12","unstructured":"NCI. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017; Available from: https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"},{"issue":"1","key":"2618_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","volume":"20","author":"CD Arvanitis","year":"2020","unstructured":"Arvanitis CD, Ferraro GB, Jain RK. The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20(1):26\u201341.","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"2618_CR14","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1158\/1078-0432.CCR-16-0399","volume":"22","author":"P Ballard","year":"2016","unstructured":"Ballard P, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22(20):5130\u201340.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"2618_CR15","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1200\/JCO.19.00457","volume":"38","author":"JCH Yang","year":"2020","unstructured":"Yang JCH, et al. Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study. J Clin Oncol. 2020;38(6):538\u201347.","journal-title":"J Clin Oncol"},{"issue":"6","key":"2618_CR16","doi-asserted-by":"publisher","first-page":"e245","DOI":"10.1016\/S1470-2045(23)00184-5","volume":"24","author":"S Yan","year":"2023","unstructured":"Yan S, et al. Global democratisation of proton radiotherapy. Lancet Oncol. 2023;24(6):e245\u201354.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2618_CR17","doi-asserted-by":"publisher","first-page":"101424","DOI":"10.1016\/j.adro.2023.101424","volume":"9","author":"HK Perlow","year":"2024","unstructured":"Perlow HK, et al. Volumetric modulated Arc therapy craniospinal irradiation utilizing a vertebral body sparing approach: an alternative approach to improve access and minimize toxicity. Adv Radiat Oncol. 2024;9(3):101424.","journal-title":"Adv Radiat Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02618-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-025-02618-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02618-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T10:48:08Z","timestamp":1745318888000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-025-02618-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,22]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2618"],"URL":"https:\/\/doi.org\/10.1186\/s13014-025-02618-7","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,22]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the local institutional review board (protocol number 2024P000907).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Felix Ehret gratefully acknowledges funding from the German Cancer Aid (Mildred-Scheel Postdoctoral Fellowship) and Accuray, Inc., and received honoraria and travel support from ZAP Surgical Systems, Inc.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"61"}}